BioSphere Medical Inc.
1050 Hingham Street
Rockland,
MA 02370
United States - Map
Phone: 781-681-7900
Fax: 781-792-2745
Web Site: http://www.biospheremed.com
| BioSphere Medical, Inc. develops, manufactures, and markets products for medical procedures that use embolotherapy. The company focuses on the treatment of symptomatic uterine fibroids, which are noncancerous, or benign, hypervascular tumors growing within or on the wall of the uterus, using a procedure called uterine fibroid embolization. Its microsphere products include Embosphere Microspheres for the treatment of uterine fibroids, hypervascularized tumors, and other arteriovenous malformations; EmboGold Microspheres for Hypervascularized tumors (other than uterine fibroids) and arteriovenous malformations; HepaSphere Microspheres to treat primary and metastatic liver cancer; and QuadraSphere Microspheres for the treatment of Hypervascularized tumors and arteriovenous malformations. The companys delivery system products include EmboCath Plus Infusion Microcatheter for the infusion of various diagnostic, embolic, and therapeutic agents and super-selective angiography within peripheral vasculature; Sequitor Steerable Guidewire for diagnostic and interventional procedures within peripheral vasculature; and Segway Guidewire for peripheral embolization procedures. In addition, it develops MR Microspheres and Resorbable Microspheres, which are in preclinical research stages to treat uterine fibroids, hypervascularized tumors, and other arteriovenous malformations. The company also sells barium delivery kits and other ancillary products in the European Union for use in gastrointestinal medical testing. BioSphere Medical, Inc. markets its embolotherapy and delivery systems products through direct sales force in the United States and France, as well as through distributors primarily in Europe, Asia, Canada, the Middle East, Africa, and South America. The company was founded in 1993 and is based in Rockland, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Richard J. Faleschini , 62
Chief Exec. Officer, Pres, Director and Member of Science & Technology Committee |
N/A
| N/A | Mr. Martin J. Joyce , 54
Chief Financial Officer and Exec. VP of Fin. & Admin. |
N/A
| N/A | Ms. Joel B. Weinstein , 58
VP of Global Marketing and Sales |
$
291.00K | N/A | Dr. Willard W. Hennemann Ph.D., 54
VP of New Product and Bus. Devel. |
$
211.00K | N/A | Mr. Peter C. Sutcliffe , 59
VP of Manufacturing |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
0.05 (1.85%) 
Profile
